NAT10 and neoplasm: To assess the effect of targeting the NAT10/ac4C/FOXP1 axis on tumor progression in vivo, we established a subcutaneous tumor model with U14‐kdNAT10 and U14‐oeFOXP1 cells in C57BL/6 mice and then treated these mice with an anti‐PD‐L1 antibody (2.5 mg kg−1 per day) on the 10th and 13th days after implantation.